Patents Assigned to Intelgenx Corp.
  • Publication number: 20240189331
    Abstract: The present disclosure relates to oral film formulations, which provide a tryptamine active agent. The disclosure more particularly relates to oral film formulations with improved buccal absorption of tryptamine active agents. The present disclosure also relates to formulations and methods for treatment of various symptoms in a patient, such as the treatment of mental health conditions.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 13, 2024
    Applicant: INTELGENX CORP.
    Inventors: Mobarik BILAL, Billal TIR, Nadine PAIEMENT
  • Publication number: 20240139101
    Abstract: This disclosure relates to oral film dosage formulations and processes for preparing oral film dosage forms for the delivery of poorly water-soluble drugs and more particularly to the preparation of oral film dosage forms that are suitable for cannabis drug delivery.
    Type: Application
    Filed: November 1, 2023
    Publication date: May 2, 2024
    Applicant: INTELGENX CORP.
    Inventors: Rima CHOUIKRAT, Nadine PAIEMENT
  • Patent number: 11957785
    Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: April 16, 2024
    Assignee: Intelgenx Corp.
    Inventors: Rodolphe Obeid, Nadine Paiement, Erick Gonzalez-Labrada
  • Publication number: 20230404937
    Abstract: Oral film formulations comprising at least one hydrophobic active agent; and a polymeric matrix at least partly composed of hydrophobic or insoluble excipients, or a combination thereof, to facilitate a controlled or sustained dissolution. Wherein when the oral film formulation has an unfavorable environment for fast dissolution, it exhibits partial disintegration within 1 to 10 minutes and a sustained rate of dissolution as confirmed by a disintegration test conducted in a limited volume petri dish, and wherein the film undergoes disintegration into smaller and smaller pieces.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 21, 2023
    Applicant: INTELGENX CORP.
    Inventors: Billal TIR, Carolin MADWAR, Nadine PAIEMENT
  • Publication number: 20230248660
    Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
    Type: Application
    Filed: March 24, 2023
    Publication date: August 10, 2023
    Applicant: Intelgenx Corp.
    Inventors: Mobarik Bilal, Rodolphe Obeid, Nadine Paiement
  • Publication number: 20230225965
    Abstract: Pharmaceutical compositions employing flavor entrapment to mitigate the unpleasant taste of active agents are described.
    Type: Application
    Filed: January 18, 2023
    Publication date: July 20, 2023
    Applicant: INTELGENX CORP.
    Inventors: Billal TIR, Nadine PAIEMENT
  • Publication number: 20230201130
    Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 29, 2023
    Applicant: INTELGENX CORP.
    Inventors: Carolin MADWAR, Nadine PAIEMENT, Rodolphe OBEID, Justin CONWAY, Erick GONZALEZ-LABRADA
  • Patent number: 11648212
    Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 16, 2023
    Assignee: Intelgenx Corp.
    Inventors: Mobarik Bilal, Rodolphe Obeid, Nadine Paiement
  • Patent number: 11602504
    Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 14, 2023
    Assignee: INTELGENX CORP.
    Inventors: Carolin Madwar, Nadine Paiement, Rodolphe Obeid, Justin Conway, Erick Gonzalez-Labrada
  • Publication number: 20230047314
    Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no.
    Type: Application
    Filed: September 25, 2022
    Publication date: February 16, 2023
    Applicant: INTELGENX CORP.
    Inventors: Nadine PAIEMENT, Rodolphe OBEID, Justin CONWAY, Billal TIR
  • Publication number: 20220409584
    Abstract: Pharmaceutical compositions with tryptamines having enhanced active stability properties are described.
    Type: Application
    Filed: June 16, 2022
    Publication date: December 29, 2022
    Applicant: INTELGENX CORP.
    Inventors: Mobarik BILAL, Nadine PAIEMENT
  • Publication number: 20220395452
    Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.
    Type: Application
    Filed: April 28, 2022
    Publication date: December 15, 2022
    Applicant: INTELGENX CORP.
    Inventors: Nadine PAIEMENT, Horst G. ZERBE, Justin W. CONWAY, Rodolphe OBEID, Ludwig AIGNER, Johanna MICHAEL
  • Publication number: 20220362164
    Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.
    Type: Application
    Filed: April 26, 2022
    Publication date: November 17, 2022
    Applicant: INTELGENX CORP.
    Inventors: Nadine PAIEMENT, Horst G. ZERBE, Justin W. CONWAY, Rodolphe OBEID
  • Patent number: 11471406
    Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: October 18, 2022
    Assignee: INTELGENX CORP.
    Inventors: Nadine Paiement, Rodolphe Obeid, Justin Conway, Billal Tir
  • Publication number: 20210393611
    Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 23, 2021
    Applicant: INTELGENX CORP.
    Inventors: Carolin MADWAR, Nadine PAIEMENT, Rodolphe OBEID, Justin W. CONWAY, Erick GONZALEZ-LABRADA
  • Publication number: 20210315802
    Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
    Type: Application
    Filed: June 14, 2021
    Publication date: October 14, 2021
    Applicant: Intelgenx Corp.
    Inventors: Rodolphe Obeid, Nadine Paiement, Erick Gonzalez-Labrada
  • Patent number: 11033493
    Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 15, 2021
    Assignee: Intelgenx Corp.
    Inventors: Rodolphe Obeid, Nadine Paiement, Erick Gonzalez-Labrada
  • Publication number: 20210022991
    Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 28, 2021
    Applicant: INTELGENX CORP.
    Inventors: Nadine PAIEMENT, Rodolphe OBEID, Justin CONWAY, Billal TIR
  • Patent number: 10828254
    Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: November 10, 2020
    Assignee: INTELGENX CORP.
    Inventors: Nadine Paiement, Rodolphe Obeid, Justin W. Conway, Billal Tir
  • Patent number: 10722476
    Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: July 28, 2020
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner